Home > PJ > News / Daily News

Return to PJ Online Home Page

The Pharmaceutical Journal Vol 267 No 7169 p495-500
13 October 2001

This article
Reprint
Photocopy


News summary


Breath-actuated inhaler improves asthma control

Patients using a breath-actuated inhaler have better control of their asthma than those using a traditional metered-dose inhaler (MDI), new research shows.

Professor David Price, department of general practice and primary care, University of Aberdeen, and colleagues compared the use of a breath-actuated MDI (Easi-Breathe) with using traditional MDI devices to deliver beclomethasone in 7,412 patients, 2,038 of whom were children. Data were obtained from the Doctors Independent Network (DIN-LINK) database, a database of medical information for 900,000 patients from 100 general practice surgeries.

Comparisons were made between the two inhaler types for patients receiving beclomethasone for the first time (“new patients”) and for those who had previously been receiving beclomethasone via a traditional MDI (“existing patients”).

The researchers found that over a 12-month period, existing patients using a breath-actuated inhaler received 24.55 per cent fewer prescriptions for the beta2 agonist salbutamol and 63.82 per cent fewer prescriptions for oral steroids, as relief medication, than those using traditional MDIs (P<0.05). They also received 55.41 per cent fewer antibiotics for respiratory infections (P<0.05). New patients using a breath-actuated inhaler were prescribed 58.73 per cent fewer oral steroids (P=0.008) and 32.74 per cent fewer antibiotics (P=0.022) than new patients using traditional MDIs. A non-significant trend was seen for new patients prescribed salbutamol.

These findings suggest that, compared with traditional MDI devices, using a breath-actuated MDI device to deliver beclomethasone results in both better asthma control and less respiratory infections, the researchers say.

Professor Price presenting the research at a press briefing in London last week following the European Respiratory Annual Congress, Berlin, said: “These findings may have important clinical and cost effective implications for the choice of inhaler type in patents with asthma.”

Back to Top


Home | Journals | News | Notice-board | Search | Jobs  Classifieds | Site Map | Contact us

©The Pharmaceutical Journal